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Background: Neuro-inflammation has long been implicated as a contributor to the progression of Alzheimer’s disease
in both humans and animal models. Type-1 interferons (IFNs) are pleiotropic cytokines critical in mediating the innate
immune pro-inflammatory response. The production of type-1 IFNs following pathogen detection is, in part, through
the activation of the toll-like receptors (TLRs) and subsequent signalling through myeloid differentiation factor-88
(Myd88) and interferon regulatory factors (IRFs). We have previously identified that neuronal type-1 IFN signalling,
through the type-1 interferon alpha receptor-1 (IFNAR1), is detrimental in models of AD. Using an in vitro approach, this
study investigated the TLR network as a potential production pathway for neuronal type-1 IFNs in response to Aβ.
Methods: Wildtype and Myd88−/− primary cultured cortical and hippocampal neurons were treated with 2.5 μM
Aβ1-42 for 24 to 72 h or 1 to 10 μM Aβ1-42 for 72 h. Human BE(2)M17 neuroblastoma cells stably expressing an
IRF7 small hairpin RNA (shRNA) or negative control shRNA construct were subjected to 7.5 μM Aβ1-42/Aβ42-1 for
24 to 96 h, 2.5 to 15 μM Aβ1-42 for 96 h or 100 ng/ml LPS for 0.5 to 24 h. Q-PCR was used to analyse IFNα, IFNβ,
IL-1β, IL-6 and TNFα mRNA transcript levels. Phosphorylation of STAT-3 was detected by Western blot analysis, and
cell viability was assessed by MTS assay.
Results: Reduced IFNα, IFNβ, IL-1β, IL-6 and TNFα expression was detected in Aβ1-42-treated Myd88−/− neurons
compared to wildtype cells. This correlated with reduced phosphorylation of STAT-3, a downstream type-1 IFN
signalling mediator. Significantly, Myd88−/− neuronal cultures were protected against Aβ1-42-induced neurotoxicity
compared to wildtype as determined by MTS assay. Knockdown of IRF7 in M17 cells was sufficient in blocking IFNα,
IFNβ and p-STAT-3 induction to both Aβ1-42 and the TLR4 agonist LPS. M17 IRF7 KD cells were also protected against
Aβ1-42-induced cytotoxicity.
Conclusions: This study confirms that the neuronal type-1 IFN response to soluble amyloid is mediated primarily
through TLRs. This production is dependent upon Myd88 and IRF7 signalling. This study suggests that targeting this
pathway to modulate neuronal type-1 IFN levels may be beneficial in controlling Aβ-induced neurotoxicity.
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Alzheimer’s disease (AD) is the most common cause of
dementia with over 44 million current sufferers world-
wide. Intracellular hyperphosphorylated tau [1] protein
and intercellular amyloid-β (Aβ) plaque deposition [2]
within the diseased brain remain the key histological ab-
normalities driving the proteinopathy, contributing to
pyramidal neuronal loss. Features of neuro-inflammation
are also evident in the AD brain. Activation and recruit-
ment of microglia to Aβ plaque deposits [3], reactive
astrogliosis [4] and elevated pro-inflammatory cytokine
load [5] have all been identified in human postmortem
tissue and in both in vivo and in vitro models of AD. Severe
neuro-inflammation, involving elevated pro-inflammatory
cytokine load, can induce cellular apoptosis directly but can
also alter the dynamics of physiological cell processes in-
cluding the classical amyloid precursor protein (APP) pro-
cessing pathway [6]. Tumour necrosis factor alpha (TNFα)
regulates in vitro Aβ production and processing by trig-
gering alterations in beta-site APP cleavage enzyme-1
(BACE-1) activity [7]. In addition, direct TNFα-induced
neurotoxicity mediated by interleukins (IL) also plays a
major role in neurodegenerative disease [8]. Aβ remains a
potent endogenous agonist for pro-inflammatory cytokine
production leading to activation of cultured microglia [9].
Recently, it has been reported that the amyloid-dependent
activation of the NALP3 inflammasome in vivo is a critical
pathway in producing IL-1β and triggering a multi-faceted
neuro-inflammatory response [10]. Our laboratory re-
cently identified a role for type-1 interferon alpha
receptor-1 (IFNAR1)-mediated signalling in Aβ-driven
neuro-inflammation [11], known to interplay with NALP3
inflammasome activation [12,13]. The consequential cyto-
kine storm triggers microglial activation and reactive
astrogliosis creating a deleterious self-perpetuating neuro-
inflammatory response by contributing to both excessive
Aβ production and direct neuro-degeneration.
The toll-like receptor signalling (TLR), a subset of the
pattern recognition receptor (PRR) super-family, remains
a major source of pro-inflammatory cytokine produc-
tion. There are 13 TLR subtypes currently identified in
humans and mice combined. Apart from endosomal
TLR3 and TRIF-dependent TLR4 activation, all signal-
ling is dependent upon the myeloid differentiation
factor-88 (Myd88) adaptor protein [14]. Subsequent TLR
signalling leads to activation of interferon regulatory fac-
tors (IRFs) and NFκB that in turn drives pro-inflammatory
cytokine production [15,16]. Whilst receptor density is
greatest in the lung and spleen, these receptors are also
widely expressed in the brain albeit at lower levels [17].
Resident microglia express all TLR subtype mRNA to fa-
cilitate their role as the brain’s ‘macrophage’. Depending
upon various stimuli from the CNS microenvironment,
these polarising cells can coordinate an M1 (neuro-protective) or M2 (reparative) innate immune response. It
is widely accepted that microglia are critical for CNS in-
flammation; however, neurons themselves also express all
TLR subtypes [18] and actively contribute to the pathogen-
induced response. Principally, the TLR system is respon-
sible for detecting foreign pathogen components (lipopoly-
saccharides and viral genomic material) as well as
endogenous material released from damaged tissue (heat
shock proteins, hyaluronic acid and mRNA). Detection of
these ligands initiates the commencement of an innate im-
mune response by which microglia, astrocytes and indeed
neurons produce cytokines, triggering removal of the for-
eign or damaged material. Aβ has been identified as a
novel endogenous ligand for many TLRs in the brain, trig-
gering a neuro-inflammatory response (reviewed in [19]).
Components of the TLR2 and TLR4 receptor complex are
required for microglial detection of Aβ, mediating their
phagocytic capacity [20,21]. Complete knockout of Myd88
in the APPSWE/PS1ΔE9 mouse model of AD ameliorated
Aβ plaque burden, silenced microglial activation and react-
ive astrogliosis [22], and rescued some cognitive impair-
ment [23]. In contrast, Myd88 heterozygous mice breed
with APPSWE/PS1ΔE9 mice displayed significant spatial
memory deficits in the T-water maze paradigm and dis-
played elevated soluble Aβ levels [24]. TLR4 mediates cyto-
kine production in APPSWE/PS1ΔE9 mice [25], and
mutations to this PRR confer reductions in microglial acti-
vation and amyloid phagocytosis [26]. The Aβ-induced and
TLR-mediated inflammatory response is critical in amyloid
processing and disease progression; however unlike glia,
how neurons conduct this response remains unclear.
Type-1 interferons (IFNs), comprised of IFNα and IFNβ,
are cytokine proteins that play an important role in host
immune response to infections, pathogens and various
diseases (reviewed in [27]). These pleiotropic cytokines are
produced via activation of numerous PRRs including the
TLR network, retinoic acid-inducible gene-1 (RIG-1), mel-
anoma differentiation-associated protein-5 (MDA-5) and
interferon gamma-inducible protein-16 (IFI-16) [28,29].
Type-1 IFNs can drive a pro-inflammatory response by ac-
tivating the JAK-STAT pathway, leading to secretion of
hallmark neuro-inflammatory cytokines TNFα, IL-6 and
IL-1β. The myriad of cytokines and chemokines secreted
provides a chemo-attractive environment, permitting cellu-
lar infiltration and inflammatory progression. Importantly,
in the absence of type-1 IFN production and signalling, this
inflammatory response fails to develop [30,31]. Although
the Tyk-2/STAT pathway has been linked to soluble Aβ1-
42 neurotoxicity [11,32], much remains unclear about
type-1 IFN signalling in various cell types, including those
in the brain.
It is critical to note that despite the complexity of
type-1 IFN production, it all remains IRF dependent. The
IRFs are well-characterised transcriptional regulators of
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lian isoforms identified. Of these nine, IRF3 and IRF7 are
the key regulators of type-1 IFN production and thus play
a central role in innate immunity [33]. Specifically, IRF7
activation is required for IFNα production resulting in an
effective immune response to a wide variety of pathogens
[33]. IRF7 is localised to the cell cytoplasm in an inactive
state and undergoes phosphorylation, interacts with vari-
ous co-activators and translocates to the nucleus upon
pathogenic insult [34]. Recently, it has been reported that
IRF7 and other type-1 IFN-regulated genes are commonly
mutated amongst the human population, altering the effi-
cacy of an innate immune response to various pathogens
[35]. Furthermore, the type-1 IFN response in ageing mice
reduces BDNF levels and doublecortin positive cells in the
dentate gyrus, shown to negatively influence cognition
and hippocampal neurogenesis [36]. The TLR network is
primarily responsible for the detection of pathogens and
this remains a major process responsible for IRF7 activa-
tion (reviewed in [37]). This activation is mediated by crit-
ical adaptor proteins TRIF, TRAF, IRAK and Myd88
[38-41] and permits a positive feedback loop by which
type-1 IFN production drives further expression of IRF7
[42,43], exacerbating the innate immune response. The Aβ
peptide is detected, but not solely, by the TLR network and
has potential to activate IRF7 in this manner, but how this
unrecognised signalling influences the neuro-inflammatory
response to amyloid has yet been addressed.
Recently, our laboratory reported the involvement of
type-1 IFNs in the neuro-inflammatory response in AD
[11]. Specifically, we identified that Aβ1-42 initiates a
deleterious type-1 IFN-mediated response in primary
cultured neurons. This implicates the importance of
neurons, not just microglia and astrocytes, in the inflam-
matory response to amyloid. In the current study, pri-
mary cultured murine neurons and human BE(2) M17
neuroblastoma cells were used to investigate the TLR
network as a potential source of this type-1 IFN re-
sponse. The neuronal type-1 IFN production in response
to Aβ1-42 was mediated through Myd88 and IRF7. Fur-
thermore, when TLR signalling was compromised by in
vitro removal of Myd88 or IRF7, cultures displayed re-
duced type-1 IFN levels and protection against Aβ1-42-
induced cell death. This study highlights the key role of
TLR signalling in the neuronal neuro-inflammatory re-




Primary antibodies used for Western blot analysis are the
following: rabbit anti-p-STAT-3 (1:1,000, Cell Signalling,
9145S, Cell Signalling Technology, Danver, MA, USA),
rabbit anti-STAT-3 (1:1,000, Cell Signalling, 4904S),mouse anti-β-actin (1:5,000, Sigma-Aldrich, A5441, Sigma-
Aldrich, St. Louis, MO, USA). Secondary antibodies used
for Western blot analysis are the following: horseradish per-
oxidase (HRP)-conjugated goat anti-rabbit (1:1,000, Dako,
P0448, Agilent Technologies, Santa Clara, CA, USA) and
goat anti-mouse (1:1,000, Dako, P0447).
Mice
All animal experiments complied with the regulatory
standards of, and were approved by, the University of
Melbourne, Faculty of Medicine, Dentistry and Health
Sciences Animal Ethics Committee (Ethics #1212477).
Myd88−/− mice on a pure C57Bl/6 background were
generated by and kindly sourced from Prof. Shizuo Akira
[44] and were mated for E14 to E16 pregnancy. Wildtype
C57Bl/6 time-mated females where sourced from the
Animal Resources Centre (ARC, Western Australia).
Mixed cortical and hippocampal neuron isolation
Mixed cortical and hippocampal neurons were isolated
from embryonic day 14 to 16 embryos as previously de-
scribed [45]. Briefly, cortices were dissected from the
foetal brains and the meningeal layers removed. Tissue
was then mechanically processed and treated with tryp-
sin (Sigma-Aldrich, T9201) and DNAse (Sigma-Aldrich,
D5025) in Krebs solution (supplemented with 0.3% BSA
w/v and 176 nM MgSO4) to produce a single-cell sus-
pension. Cells were allowed to adhere for 2 h, to remove
potential contaminating fibroblasts and glia, before cultures
were plated at 106 cells/ml in plating media (Neurobasal
media containing B27 supplement (Gibco, 17504–044, Life
Technologies, Carlsbad, CA, USA) and 2% FBS). The fol-
lowing day, FBS was removed from the media and cultures
were supplemented with fresh culture media (Neurobasal
media containing B27 supplement) every 2 days until treat-
ment. Cultures were treated at 7 days in vitro. Purity of cul-
tures was confirmed to be >95% neurons by NeuN and
GFAP staining to identify neurons and glia, respectively.
M17 neuroblastoma cells
Human BE(2) M17 neuroblastoma cells (ATCC® number:
CRL-2267™) were cultured in T75 flasks with culture
medium (OptiMEM (Gibco), 5% FBS, 0.5% penicillin-
streptomycin (Gibco)) at 37°C/5% CO2 until 90% conflu-
ent. Cells were plated at 2 × 105 cells/ml in 6-cm dishes
for 24 h prior to treatment.
Generation of M17 IRF7 knockdown cell line
IRF7 knockdown (IRF7 KD) and negative control (NC)
knockdown M17 cells were generated using commer-
cially available small hairpin RNA (shRNA) plasmid con-
structs (Origene, Rockville, MD, USA). Briefly, M17 cells
were transfected using Fugene®HD (Promega, Madison,
WI, USA) with HuSH shRNA plasmids containing an
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scrambled shRNA cassette. Clonal cell lines were gener-
ated using the selectable marker puromycin (0.5 μg/ml,
Gibco, A11138-03). Successful knockdown of IRF7 (>70%)
was confirmed by QPCR where IRF7 levels in IRF7 KD
M17 cells were compared to their NC M17 cell counter-
parts (Additional file 1: Figure S1).
Amyloid-beta preparation and treatment
Amyloid peptide stocks were generated according to
protocol by [46]. The amyloid-β (Aβ) 1-42 (peptide cor-
responding to amino acids 1 to 42, GenecBio, A-42-T-1)
peptide was initially reconstituted in 1,1,1,3,3,3-hexa-
fluoro-2-propanol at 0.5 mg/mL, lyophilised, and stored
at −80°C until required. The peptide was then dissolved
in a 5 mM NaOH vehicle and protein concentration
determined by absorbance spectrophotometry at 214 nm
as previously described [47]. This enhances the Aβ pep-
tide solubility and lengthens the time frame in which
toxicity is induced [46,48-51]. These preparations lead to
globular aggregate structures that resemble the oligo-
meric confirmation rather than elongated fibril struc-
tures [52-54]. Primary neuronal cultures were then
treated with 0.5 to 10 μM Aβ1-42 or vehicle for up to 72
h in treatment medium (Neurobasal media containing
anti-oxidant free B27 supplement (Gibco, 10889038)).
M17 NC shRNA and M17 IRF7 KD cell cultures were
treated with 2.5 to 15 μM Aβ1-42 for up to 96 h in fresh
serum-reduced culture medium (2% FBS). The final
NaOH concentration in the culture medium was <5 nM
and shown to be non-toxic.
Lipopolysaccharide preparation and treatment
Lipopolysaccharides from Escherichia coli 026:B6 (LPS,
Sigma-Aldrich, L8274) were initially reconstituted in
phosphate-buffered saline (PBS) to yield a concentration
of 1 mg/ml, and aliquots were stored at −80°C until re-
quired. M17 human neuroblastoma cells were then
treated with 100 ng/ml LPS for 0.5 to 24 h in fresh
serum-reduced culture medium (2% FBS).
Protein extraction
Following treatment, primary neuronal and M17 cell
cultures were collected via cell scraping in ice-cold PBS.
After centrifugation at 5,000 g, cell pellets were soni-
cated in lysis buffer (50 mM tris, 1% Triton x-100, 1%
SDS, PhosphoSTOP® and protease inhibitors (Roche, Basel,
Switzerland), pH 7.4) and protein concentrations deter-
mined by Bradford assay (Bio-Rad, Hercules, CA, USA).
Western blot analysis
A 50 μg of protein was resolved on 10% acrylamide SDS
PAGE gels and transferred to polyvinylidene fluoride
(PVDF) membranes by semi-dry transfer. Membraneswere blocked with 5% w/v skim milk powder in TBS-T
for 1 h at room temperature (≈20°C) before overnight
incubation with primary antibodies at 4°C. Membranes
were washed in TBS-T before being incubated with HRP-
conjugated secondary antibodies (diluted in 5% (w/v) BSA
in TBS-T) for 120 min at room temperature (≈20°C). After
additional washing in TBS-T, signals were detected using
an ECL™ prime Western blotting detection kit (Amersham,
RPN2232, GE Healthcare, Little Chalfont, UK) and visua-
lised using the ChemiDoc™ MP system (Bio-Rad).
RNA isolation and cDNA synthesis
Cells were lysed in TRIzol® (Life Technologies, 15596018)
and RNA isolated per manufacturer’s instructions with
concentrations determined by the Nanodrop 1000 spec-
trophotometer (Thermo Scientific, Waltham, MA, USA).
A 1 μg quantity of RNA was reversed transcribed into
cDNA using a high-capacity cDNA reverse transcription
kit (Applied Biosystems, Life Technologies, USA, 4368814)
according to manufacturer guidelines. cDNA was diluted
1:3 in DEPC-treated dH2O for use in quantitative PCR
(Q-PCR).
Quantitative PCR (Q-PCR)
All Q-PCR was performed in standard 384-well plates
using the 7900HT fast real-time PCR system (Applied
Biosystems, Life technologies, USA). Taqman probes
(Applied Biosystems, Life technologies, USA) were used
to analyse huIFNα (Hs00256882_sl), huIFNβ (Hs010
77958_sl), UBC (Hs00824723_m1), muGAPDH (Mm99
999915_m1), muIFNβ (Mm00439552_s1), muIL-1β (Mm
01336189_m1), muIL-6 (Mm00446190_m1) and muTNFα
(Mm00443258_m1) under the following cycle parameters:
50°C for 2 min, 94.5°C for 10 min, (97°C for 30 s, 59.7°C
for 60 s) × 40 repeats. The SYBR green system was used to
analyse muIFNα and muGADPH using the following pri-
mer sequences (Geneworks, Hindmarsh, SA, Australia):
GADPH forward: 5′ ATCTTCTTGTGCAGTGCCAGC
3′, GADPH reverse: 5′ ACTCCACGACATACTCAGC
ACC 3′, muIFNα forward: 5′ GCAATCCTCCTAGACT
CACTTCTGCA 3′, muIFNα reverse 1: 5′ TATAGTT
CCTCACAGCCAGCAG 3′, muIFNα reverse 2: 5′
TATTTCTTCATAGCCAGCTG 3′, muTLR2 forward: 5′
TGCTTTCCTGCTGAAGATTT 3′, muTLR2 reverse: 5′
TGTACCGCAACAGCTTCAGG 3′, muTLR4 forward:
5′ ACCTGGCTGGTTTACACGTC 3′, muTLR4 reverse:
5′ TGTCCAGAGACATTGCAGAA 3′. SYBR green
Q-PCR was then performed under the following
temperature regulations: 95°C for 20 min, (95°C for 30 s,
60°C for 90 s) × 40 repeats, 95°C for 15 min, 60°C for 15
min, 95°C for 15 min. Fold change in mRNA levels were
then calculated using the ΔΔct method (2-ΔΔCt) [55]. Cycle
threshold (Ct) values were obtained from the linear gradi-
ent section of each fluorescent PCR amplification curve.
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genes of interest were then normalised back to the
GAPDH housekeeping gene, yielding ΔCt values. The
calculated ΔCt of the Aβ treatment groups were then nor-
malised against respective genotype-specific vehicle con-
trol samples (ΔΔCt). As all ΔΔCt values were calculated
from the linear gradient amplification curve, conferring
100% enzymatic efficiency, and PCR is an exponential
process, ΔΔCt values were then converted to fold
change (fold change = 2(−ΔΔCt)). All Q-PCR data ex-
pressed throughout this publication has been calculated
using this method.
MTS assay
Cell viability was measured by the cellular ability to metab-
olise 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphe-
nyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega) in
the presence of phenazine methosulfate to a formazan
product, as described previously [56]. Viability of treated
samples was expressed as a percentage of light absorbance
at 490 nm of the vehicle control, with all experiments per-
formed in triplicate. Staurosporine (1 μM) was used to
induce cellular apoptosis and used as a positive control for
apoptotic cell death in the neuronal cultures.
Statistical analysis
For all Q-PCR, MTS assay and Western blot densitometry
data, an unmatched two-way ANOVA was performed for
each time point/concentration with cellular genotype as
the fixed variable. A Bonferroni post hoc test was then
used to determine statistical significance (p < 0.05) be-
tween genotype groups. Graphical data is displayed as
mean ± SEM.
Results
The type-1 IFN response to Aβ1-42 is Myd88 dependent
in primary cultured neurons
Previously, we have confirmed that neurons alone are cap-
able of initiating a type-1 IFN response to soluble amyloid
[11]. The TLR system has previously been implicated in the
detection of soluble amyloid [57], and classical TLR signal-
ling leads to production of type-1 IFNs. We confirm that
TLR4 and TLR2, albeit at lower levels, are expressed in our
primary cultured mixed cortical and hippocampal neurons
(Additional file 2: Table S1). A critical adapter protein
required for the majority of TLR-mediated signalling is
Myd88; thus, we used Myd88−/− neuronal cultures to inves-
tigate the source of type-1 IFN production in response to
Aβ1-42. Wildtype and Myd88−/− neurons were treated with
2.5 μM Aβ1-42 for 24 to 72 h. This Aβ1-42 concentration
routinely gives ≈ 50% cell death, thus simulating amyloid
neurotoxicity and allowing surviving cells to react to the
neuro-inflammatory environment [11]. Q-PCR identified
attenuated IFNα (4.6-fold vs. 1.5-fold at 24 h, 13.7-fold vs.2.5-fold at 72 h, Figure 1A) and IFNβ (3.1-fold vs. 1.3-fold
at 24 h, 7.0-fold vs. 2.6-fold at 72 h, Figure 1B) mRNA
transcript levels in Aβ1-42-treated Myd88−/− cultures com-
pared to wildtype. Type-1 IFNs directly stimulate the JAK-
STAT cascade to initiate pro-inflammatory cytokine tran-
scription; hence, we investigated the phosphorylation of
STAT-3 in these cultures. Western blot identified elevated
tyrosine 705 phosphorylation of STAT-3, at 24 and 72 h, in
Aβ1-42-treated wildtype neuronal cultures. Densitometry
confirmed that this phosphorylation was significantly re-
duced in Myd88−/− neuronal cultures (1.4-fold vs. 0.5-fold
at 24 h, 5.3-fold vs. 2.8-fold at 72 h, Figure 1C,D, Additional
file 3: Figure S3). Synthetic peptides [58] and potential
endotoxin contaminants [59] possess the ability to act as
DAMPs and in turn trigger an immune response. To con-
firm that the observed type-1 response is Aβ1-42 specific
and not an artefact response from a foreign peptide, neur-
onal cultures were also treated with the control Aβ42-1
peptide. Significantly, neuronal Aβ42-1 treatment failed to
generate type-1 IFN expression (Additional file 4: Figure
S2A) and STAT-3 phosphorylation (Additional file 4: Figure
S2B) in WT neurons indicating that this innate immune
response is Aβ1-42 specific. This data confirms that neu-
rons alone have the capacity to initiate a type-1 IFN re-
sponse specifically against the Aβ1-42 peptide. This
response is dependent upon Myd88 signalling, a critical
adaptor protein in the TLR network.
Hallmark pro-inflammatory type-1 IFN-regulated cytokine
expression is reduced in Myd88−/− neuronal cultures
following Aβ1-42 insult
The products of type-1 IFN-driven JAK-STAT signalling
are a myriad of pro-inflammatory cytokines that in turn
drive the innate immune response. Interleukins and TNFα
are critical cytokines in potentiating this immune response
and are upregulated in settings of amyloid pathology [60];
thus, we assessed their expression in Myd88−/− neuronal
cultures. Wildtype and Myd88−/− neurons were treated
with 2.5 μM Aβ1-42 for 24 to 72 h. Expression of the hall-
mark pro-inflammatory cytokines IL-1β (3.2-fold vs. 1.3-
fold at 24 h, Figure 2A), IL-6 (21.4-fold vs. 3.0-fold at 24 h,
Figure 2B) and TNFα (3.2-fold vs. 1.0-fold at 24 h, 4.6-fold
vs. 1.0-fold at 48 h, 6.3-fold vs. 1.7-fold at 72 h, Figure 2C)
were decreased in Myd88−/− neurons compared to wild-
type cultures in response to Aβ1-42. This data confirms a
neuronal source of hallmark pro-inflammatory cytokine
secretion in response to amyloid. This response, comprised
of interleukins and TNFα, is governed by TLR-Myd88-
dependent signalling.
Removal of Myd88 confers protection against Aβ1-42
toxicity in primary cultured neurons
To investigate the overall effect of reducing type-1 IFN
production and signalling through removal of Myd88,
Figure 1 Myd88−/− neurons display reduced type-1 interferon load and signalling in response to Aβ1-42 insult. Wildtype and Myd88−/− primary
cultured murine mixed cortical and hippocampal neuronal cultures were treated with 2.5 μM Aβ1-42 for 24 to 72 h. (A) IFNα and (B) IFNβ
mRNA levels were analysed by Q-PCR (*p < 0.05, n = 5 to 6, unmatched two-way ANOVA, Bonferroni post hoc test). (C) STAT-3 tyrosine 705
phosphorylation of whole cell extracts was measured by Western blot. (D) Corresponding densitometry (*p < 0.05, n = 5, unmatched two-way
ANOVA, Bonferroni post hoc test). For densitometry calculations, phosphorylation intensity was measured in arbitrary units (A.U.) and normalised to the
STAT-3:β-actin intensity ratio. All graphical data is displayed as mean ± SEM with treatment time on the x axis. Full-size uncropped Western blots can
be viewed in Additional file 4: Figure S2.
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and neuronal viability was measured by MTS assay.
Myd88−/− neurons were significantly less susceptible to
Aβ1-42-induced neurotoxicity compared to wildtype
cells (69.9% vs. 86.1% viability with 2.5 μM, 56.8% vs.
80.4% viability with 5 μM, 44.3% vs. 58.8% viability with
10 μM, Figure 3). No difference in viability between ge-
notypes in response to the apoptosis-inducing stauros-
porine was identified. This finding suggests that a
reduction in type-1 IFN and hallmark pro-inflammatory
cytokines, via removal of Myd88, confers protection
against soluble amyloid cytotoxicity.
The type-1 IFN response to Aβ1-42 is IRF7 dependent and
mimics an LPS-induced type-1 IFN signature in human
BE(2) M17 neuroblastoma cells
IRF7 has been reported as the critical mediator of type-1
IFN production and is a major downstream signalling
molecule in Myd88-dependent and independent TLR
cascades [61]. To investigate if IRF7 is critical in soluble
amyloid-driven type-1 IFN production in human M17
neuroblastoma cells, we established a stable IRF7 shRNA
cell line and treated with 7.5 μM Aβ1-42 for 24 to 72 h.
Q-PCR identified decreased IFNα (3.1-fold vs. 0.5-fold at
48 h, 3.8-fold vs. 0.8-fold at 72 h, 3.9-fold vs. 1.2-fold at96 h, Figure 4A) and IFNβ (1.9-fold vs. 0.6-fold at 48 h,
2.3-fold vs. 0.8-fold at 72 h, 2.9-fold vs. 1.1-fold at 96 h,
Figure 4B) mRNA transcript levels in Aβ1-42-treated
M17 IRF7 KD cells compared to M17 NC shRNA cul-
tures. This data is supported by similar findings using an
alternative M17 IRF7 KD clonal cell line with 77%
knockdown efficiency (Additional file 5: Figure S4). As
the amyloid peptide is detected by many TLR isoforms,
we utilised LPS to ascertain a TLR4-specific type-1 IFN
response profile and compared this to the Aβ1-42 data.
IRF7 KD shRNA and NC shRNA M17 cells were treated
with 100 ng/ml LPS for 30 min to 24 h. Q-PCR showed
decreased IFNα (5.2-fold vs. 0.6-fold at 30 min, 4.2-fold
vs. 1.0-fold at 1 h, 6.8-fold vs. 0.7-fold at 2 h, Figure 4C)
and IFNβ (2.4-fold vs. 1.1-fold at 2 hours, 2.8-fold vs.
1.0-fold at 24 hours, Figure 4D) mRNA levels in LPS-
stimulated M17 IRF7 KD cells compared to NC shRNA
cultures. Western blot analysis identified a trend for de-
creased STAT-3 phosphorylation levels at 24 h (5.0-fold
vs. 3.4-fold, t = 2.064, DF = 5) and a significant reduction
at 72 h (6.2-fold vs. 3.1-fold) post-Aβ1-42 treatment
in M17 IRF7 KD cells compared to NC cultures
(Figure 4E,F, Additional file 6: Figure S5). Similarly, LPS-
induced STAT-3 phosphorylation levels were reduced at
2 h (4.9-fold vs. 2.7-fold) and 24 hours (6.9-fold vs. 2.0-
Figure 2 Removal of Myd88 in Aβ1-42-treated neuronal cultures confers reductions in hallmark pro-inflammatory cytokine secretion. Wildtype
and Myd88−/− primary cultured murine mixed cortical and hippocampal neuronal cultures were treated with 2.5 μM Aβ1-42 for 24 to 72 h. Q-PCR
was performed to analyse (A) IL-1β, (B) IL-6, and (C) TNFα mRNA transcript levels (*p < 0.05, ***p < 0.001, n = 5 to 6, unmatched two-way ANOVA,
Bonferroni post hoc test). All data is displayed as mean ± SEM with treatment time on the x axis.
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file 7: Figure S6). This data confirms that both type-1
IFN responses to the peptide TLR ligand, Aβ1-42 and
the TLR4 selective agonist, LPS, are IRF7 dependent in
human BE(2) M17 neuroblastoma cells. This finding im-
plies that TLR4 detection of amyloid and IRF7 signalling
contributes to the net neuronal type-1 IFN response to
soluble amyloid.Figure 3 Myd88−/− neurons are protected against soluble Aβ1-42
toxicity. Wildtype and Myd88−/− neuronal cultures were treated with
1 to 10 μM Aβ1-42 for 72 h and an MTS assay for cell viability was
performed (*p < 0.05, n = 9, unmatched two-way ANOVA, Bonferroni
post hoc test). Staurosporine (1 μM) was used as a positive control for
neuronal cell death. Data is displayed as mean ± SEM with treatment
concentration on the x axis.Reduction of IRF7 levels confers protection against
Aβ1-42 toxicity in human BE(2) M17 neuroblastoma cells
Previously, and in the current study, we have reported
that reducing type-1 IFN secretion in response to amyl-
oid in neuronal cultures affords cellular protection [11].
Thus, we assessed the effect on cytotoxicity of decreased
type-1 IFN production and signalling in response to
Aβ1-42 using M17 IRF7 KD cells. M17 IRF7 KD cells
and NC shRNA cultures were treated with 2.5 to 15 μM
Aβ1-42 for 96 h, and an MTS assay was performed to
evaluate cellular viability. M17 IRF7 KD cells were sig-
nificantly protected against 7.5 μM Aβ1-42 (61.8% vs.
103.1% viability) compared to their NC shRNA counter-
parts with a protective effect also suggestive at 10 μM
Aβ1-42 (40.5% vs. 62.3% viability, t = 2.128, DF = 4)
(Figure 5). This data suggests that reducing IRF7-
dependent production of type-1 IFNs in response to
Aβ1-42 confers a protective phenotype in human BE(2)
M17 neuroblastoma cells.
Discussion
Deposition of the Aβ peptide and formation of insoluble
plaques are hallmark pathologies associated with AD.
However, the extent of plaque formation fails to correl-
ate with disease progression [62] and therefore it has
been considered that the soluble amyloid oligomers are
Figure 4 (See legend on next page.)
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Figure 4 The neuronal type-1 IFN response to Aβ1-42 is IRF7 dependent and mimics an LPS-induced interferon signature. Human BE(2) M17
neuroblastoma cells, transfected with an IRF7 knockdown (KD) construct or negative control (NC) plasmid, were treated with 7.5 μM Aβ1-42 for
24 to 96 h. Q-PCR was performed to analyse (A) IFNα and (B) IFNβ mRNA levels post-treatment (*p < 0.05, n = 9 to 12, unmatched two-way
ANOVA, Bonferroni post hoc test, alternative clone data can be viewed in Additional file 4: Figure S2). Cells were treated with 100 ng/ml LPS for 0.5
to 24 h and (C) IFNα and (D) IFNβ mRNA levels were analysed by Q-PCR (*p < 0.05, n = 7 to 9, unmatched two-way ANOVA, Bonferroni post hoc
test). (E) The phosphorylation of STAT-3 in the Aβ1-42-treated cultures was analysed by Western blot analysis. (F) Corresponding densitometry.
(**p < 0.01, n = 6, unmatched two-way ANOVA, Bonferroni post hoc test). (G) The protein lysates of the LPS-treated cells were also analysed for
STAT-3 phosphorylation by Western blot with (H) corresponding densitometry (*p < 0.05, n = 12, unmatched two-way ANOVA, Bonferroni post hoc
test). For densitometry calculations, phosphorylation intensity was measured in arbitrary units (A.U.) and normalised to the STAT-3:β-actin intensity
ratio. All graphical data is displayed as mean ± SEM with treatment time on the x axis. Full-size uncropped Western blots of Aβ- and LPS-treated
cultures can be viewed in Additional file 6: Figure S5 and Additional file 7: Figure S6, respectively.
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neuro-degeneration [63,64]. The precise mechanisms of
soluble Aβ-induced neurotoxicity however are still poor-
ly understood. Neuro-inflammation has been implicated
in AD progression, but the exact contribution of each
CNS-residing cell type in this response remains unclear.
Microglia, the resident inflammatory cells of the CNS,
remain critically important for the clearance of Aβ; how-
ever, it is ultimately the neuronal populations that
respond detrimentally to the neuro-inflammatory envir-
onment in AD and are indeed the cells lost in the path-
ology [65,66]. We have previously established a role for
type-1 IFNs in animal and cell models of Aβ toxicity
[11]. Specifically, we identified neuronal populations as a
source of type-1 IFN secretion in response to soluble Aβ
insult. This current study investigated TLR signalling
pathways as a potential origin for this neuronal type-1
IFN response to Aβ. Myd88 remains a critical adaptor
protein in the majority of TLR pathways and drives IRF7
activation, in turn upregulating the expression and sub-
sequent production of type-1 IFNs. Type-1 IFN secre-
tion and downstream signalling via p-STAT-3 was
downregulated in Myd88−/− primary neurons following
Aβ1-42 challenge. This finding correlated with reductionsFigure 5 Knockdown of IRF7 in human BE(2) M17 neuroblastoma
cells confers protection against Aβ1-42. Human BE(2) M17
neuroblastoma cells, transfected with an IRF7 knockdown (KD)
construct or negative control (NC) plasmid, were treated with 2.5 to
15 μM Aβ-42 for 72 h and an MTS assay to measure cell viability was
performed (**p < 0.01, n = 5, unmatched two-way ANOVA, Bonferroni
post hoc test). All data is displayed as mean ± SEM with treatment
concentration on the x axis.in hallmark pro-inflammatory cytokines IL-1β, IL-6 and
TNFα and resulted in neuro-protection against soluble
Aβ. We show that knockdown of IRF7 is sufficient to
abolish the type-1 IFN response to both the selective
TLR4 agonist LPS and the indiscriminate TLR ligand
Aβ1-42 in human neuroblastoma M17 BE(2) cells. Fur-
thermore, IRF7 knockdown resulted in protection against
Aβ1-42 toxicity.
TLRs, a super-family of pattern recognition receptors,
are the host’s primary detectors of foreign pathogens
and mediate the initial type-1 IFN response in the innate
immune response [67]. A myriad of TLR subtypes are
capable of detecting Aβ and initiating an innate immune
response against the neurotoxic peptide [57,68,69].
Myd88 is a critical adaptor protein for all TLR signalling
except for TLR3 and Myd88-independent TLR4 ac-
tivation. The involvement of Myd88 in animal models
of amyloidosis remains controversial and somewhat
conflicted. Mice over-expressing APP and PS1 on a
Myd88−/− background showed reduced soluble and in-
soluble amyloid load at 10 months correlating with re-
ductions in reactive astrogliosis and microglial activation
[22]. These same mice appeared to show no spatial
learning improvement in the Morris water maze com-
pared to APPswe/PS1ΔE9 mice alone but interestingly, re-
moval of Myd88 was sufficient to improve this outcome
regardless of transgene expression [23]. APPswe/PS1ΔE9
mice on a heterozygous Myd88 background also showed
reduced plaque deposition but elevated soluble Aβ
levels. These mice were found to have reduced brain IL-
1β mRNA and had accelerated spatial memory deficits
in the T-water maze [24]. Most recently, APPswe/PS1ΔE9
mice on a Myd88 deficient background showed no
changes in amyloid levels or immune cell infiltration but
displayed a reduced life expectancy [70]. All these
reports ultimately focus on the astrocyte and microglial
response to amyloid load and how Myd88 absence
affects this process. Still, there remain conflicting con-
clusions arising from these animal models.
Neuro-inflammation is an intricate process with mul-
tiple signalling cascades and critical cellular processes
driving pathogen clearance. Our study aimed to simplify
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trolled in vitro approach to assess the impact of Myd88
signalling in response to soluble amyloid. In this study,
we focus on the impact of Myd88 removal in neurons
and how this may alter the type-1 IFN response to the
amyloid peptide. Removal of Myd88 in primary neur-
onal cultures conferred reductions in type-1 IFNs and
hallmark pro-inflammatory cytokines IL-1β, IL-6 and
TNFα compared to wildtype when challenged with
Aβ1-42. This reduction in pro-inflammatory cytokine
expression in the Myd88−/− cells also coincided with de-
creased p-STAT-3 levels, a downstream type-1IFN sig-
nalling mediator. This data supports the hypothesis that
the TLR network is responsible for detecting soluble
amyloid [19]. Furthermore, we hypothesise that the
neuronal type-1 IFN response to amyloid occurs via a
TLR-mediated mechanism. This type-1 IFN response is
biphasic in nature which remains a common character-
istic of the type-1 IFN signature displayed upon patho-
genic infection [71-73]. This release begins from 24 h
post-Aβ insult, returns to baseline by 48 h and enters a
secondary ramping phase from 72 h. The lack of signifi-
cant difference between the wildtype and Myd88−/−
neuronal type-1 IFN expression pattern at 48 h post-Aβ
treatment can be explained by the existence of this wild-
type biphasic response.
It is well accepted that a neuro-inflammatory environ-
ment, if not controlled, is deleterious to neuronal viabil-
ity and disease progression. IL-1β, IL-6 and TNFα
remain as hallmark pro-inflammatory cytokines that can
trigger necrosis, apoptosis and excitotoxicity. We have
shown that Myd88−/− neuronal cultures, with reduced
pro-inflammatory cytokine load, are protected against
Aβ1-42 when compared to wildtype cells. These findings
suggest that limiting the pro-inflammatory environment
induced by amyloid, at least in a neuronal context, is bene-
ficial in promoting neuro-protection. Neuro-inflammation
is a complex but coordinated event that is tightly regulated
by specific cellular processes but also the timing in which
they occur. The timing of individual pro-inflammatory
cytokine and chemokine release is crucial in recruitment of
immune cells to the inflamed site and ensuring that this
microenvironment facilitates an efficient immune response.
Our data suggests that neurons, in response to amyloid, re-
lease an initial short-term interleukin pro-inflammatory
component and potentiated TNFα component that corre-
lates well with the time frame of Aβ1-42-induced neuro-
toxicity. Whilst IL-1β, IL-6 and TNFα pro-inflammatory
cytokine secretions in neuro-inflammation share great
interplay, the regulatory mechanisms governing their pro-
duction differ [74-77]. Type-1 IFNs remain critical to the
inflammatory response and can regulate the NALP3
inflammasome responsible for IL-1β production [78], pre-
viously implicated in AD pathology [10]. It remains unclearif alterations in type-1 IFN expression alone are suffi-
cient to modulate the Aβ inflammasome or if other sig-
nalling pathways are involved, providing scope for
further investigation.
Type-1 IFN production involves multiple signalling cas-
cades. Although TLR activation is a primary source of
type-1 IFNs [28], other pattern recognition receptors can
also be responsible. Retinoic acid-inducible gene-1 (RIG-
1), melanoma differentiation-associated protein-5 (MDA-
5) and interferon gamma-inducible protein 16 (IFI-16) are
all examples of TLR-independent activators of the type-1
IFN response [29]. Furthermore, complement can stimu-
late plasmacytoid dendritic cells to produce IFNα [79] and
is a major component of the innate immune response.
Despite this myriad of potential type-1 IFN secretion path-
ways, they all converge on the phosphorylation/activation
of IRFs to initiate type-1 IFN gene transcription. Specific-
ally, IRF7 is required for type-1 IFN production [61] and
is an important regulator for many of the aforementioned
innate immunity signalling cascades. Upon stimulation of
human neuroblastoma M17 cell cultures with the TLR4
agonist LPS we found that IRF7 knockdown was sufficient
to ablate the type-1 IFN response to the bacterial endo-
toxin. This data supports previous dogma that stimulation
of TLR4 induces a type-1 IFN response through IRF7 acti-
vation [80,81]. Initially, this response is mediated by a
TRIF-dependent interaction but subsequent type-1 IFN
production remains Myd88 dependent [82]. LPS induces a
well-characterised TLR4-mediated response and is useful
as a pharmacological tool in this respect; however, Aβ as
an endogenous pathogenic ligand interacts with numerous
receptors associated with the innate immune system [19].
We identified that knockdown of IRF7 was sufficient to
decrease type-1 IFN expression and downstream p-STAT-
3 signalling in response to Aβ1-42. This similarity between
the type-1 IFN release profile from cultures stimulated
with either LPS or Aβ infers that TLR4 detection of amyl-
oid contributes to the net type-1 IFN response. Under
conditions of neuronal stress [83] or innate immune sys-
tem priming [82], TLR4 signalling can induce a robust
IRF7-dependent type-1IFN response. Our findings suggest
that a TLR4-IRF7 driven type-1 IFN response is involved
in the cellular response to soluble amyloid.
Alongside IRF7, IRF3 is also critical in producing a
type-1 IFN response to pathogenic material [84]. TLR4
activation leads to the formation of the TBK1/IKKi com-
plex and can phosphorylate both IRF3 [85] and IRF7
[86] leading to DNA binding and type-1 IFN transcrip-
tion. Furthermore, activation of NFκB, downstream of
TLR4, has been implicated in Aβ signalling and apop-
totic neurons in human AD brains [87,88]. NFκB is cap-
able of modulating both IRF3 and IRF7 activation via
transcription and production of pro-inflammatory cyto-
kines [89]. The precise contribution of TLR-mediated
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to amyloid and potential interplay with IRF7 has yet to
be explored and warrants further investigation. It is
likely that TLR4 binding is a significant component of
Aβ-induced type-1 IFN production; however, the overall
response is likely to be the summation of many activated
sensors of the innate immune system.
Considering Myd88−/− neurons secrete reduced type-1
IFN in response to Aβ and exhibit significant neuro-
protection, we assessed viability of IRF7 knockdown M17
cultures. Similar to the Myd88−/− cells, M17 IRF7 KD cells
were protected against Aβ1-42-induced cytotoxicity. We
therefore hypothesise that reducing neuronal type-1 IFN
levels in response to Aβ will be beneficial for cellular sur-
vival. The current study uses the Aβ1-42 peptide as the
sole ligand to trigger an innate immune response. As amyl-
oid is a neurotoxic peptide, the neuronal cultures are under
duress and can release DAMPs which are readily recog-
nised by PRRs. The subsequent release of neuronal IL-1β,
IL-6 and TNFα actively contributes to the neuro-
inflammatory environment and drives excitotoxicity
[90]. Despite amyloid-induced signalling occurring prior
to that of DAMPs, it remains difficult to predict what
proportion of the inflammatory response is induced
purely by amyloid rather than cellular stress and debris.
Delineating these pathways will be important in identi-
fying the exact initial binding partners of Aβ and may
reveal novel therapeutic targets.
The concept of inflammatory homeostasis controlled by
neuronal reflex activity is well established with cholinergic
activity being implicated in negatively regulating pro-
inflammatory responses [91,92]. Indeed, genetic ablation of
the α7 nicotinic acetylcholine (ACh) receptor (nAChR) in
mice leads to loss of vagal nerve-induced suppression of
TNFα [93] and α7 agonists can significantly inhibit the
cytokine production induced by pathogenic TLR ligands
[94]. Indeed, cholinergic neural activity activates the
CREB/cfos transcriptional pathways leading to inhibition
of NFκB in various innate and adaptive immune cells.
TLR activation via various pathogens and Aβ is a major
driver of NFκB activity, and thus these two signalling
pathways compete against each other to govern the pro-
inflammatory cytokine response to pathogenic insult and/
or tissue damage [95]. In the context of AD, patients com-
monly display decreased cerebral and hippocampal α7
nAChR expression and cholinergic activity [96]. As men-
tioned previously, dysregulation of the cholinergic system
can lead to a pro-inflammatory imbalance and this leads
to declines in executive function and brain metabolism in
mice [97]. MicroRNA-132 is a negative regulator of synap-
tic AChesterase [98] and has recently been identified as
decreased in early stages of AD [99], suggesting that
decreased cholinergic activity and hence elevated pro-
inflammatory cytokine load is an early event contributingto disease progression. Findings from our study reveal a
novel mechanism by which TLR signalling, in opposition
to cholinergic activity, drives type-1 IFN production and
pro-inflammatory cytokine secretion in response to Aβ.
This finding highlights a potential mechanism by which
neuro-inflammation is exacerbated in the absence of effi-
cient cholinergic control in AD.
Whilst our findings support developing therapeutics
which can modulate type-1 IFN levels in conditions of
amyloidosis, agents targeting neuro-inflammation should
be treated with caution. Type-1 IFNs are pleiotropic in na-
ture and behave remarkably different depending on cell
type. Indeed, type-1 IFNs are critical in viral immunity and
beneficial inflammatory processes needed for clearance of
amyloid. Targeting the TLR network therapeutically may
prove a viable way of limiting type-1 IFN levels, but it is
critical that the degree of modulation, the timing of thera-
peutic intervention and cell-type specificity be taken into
account. In support of this, APPswe/PS1ΔE9 mice carrying a
non-functional TLR4 mutant allele displayed decreased
microglial activation and increased amyloid deposition and
were more vulnerable to spatial learning memory deficits
in the Morris water maze [26]. Furthermore, TLR4 is re-
quired for microglial phagocytosis of degenerating axons
and efficient removal of cellular debris [83]. In addition,
mice lacking TLR9 develop a spontaneous anxious pheno-
type due to lack of non-canonical NFκB activation, crucial
in controlling anti-inflammatory cascades [100]. It is clear
from these findings that complete removal of the TLR re-
sponse remains deleterious due to suppression or lack of
coordination in the immune response. Rather a fine bal-
ance is required where a neuro-inflammatory response is
initiated, clearance of amyloid occurs and inflammation is
resolved. In AD, where neuro-inflammation remains
chronically activated, therapeutic intervention is required.
Our findings identify that the neuronal type-1 IFN re-
sponse to amyloid is deleterious to neuronal viability and
that this response is TLR-Myd88-IRF7 dependent. This
highlights a novel production pathway of the type-1 IFNs,
a master regulator of innate immunity, in Aβ-induced
neuro-inflammation. The neuronal origin of this finding
highlights the importance in understanding the cell-
specific responses to amyloid. This knowledge will be crit-
ical in identifying and targeting novel signalling pathways
to limit both the neuro-inflammatory component and sub-
sequent neuronal cell death of AD.Additional files
Additional file 1: Figure S1. Evaluation of IRF7 knockdown efficiency in
human BE(2) M17 human neuroblastoma cells. M17 cells stably
transfected with an IRF7 shRNA or corresponding negative control shRNA
plasmid were analysed by Q-PCR to evaluate knockdown efficiencies. Data for
IRF7 knockdown is expressed as fold change normalised to corresponding
Minter et al. Journal of Neuroinflammation  (2015) 12:71 Page 12 of 14negative control transfected cells (nominal value of 1). Graphical data is
displayed as mean ± SEM (n = 4).
Additional file 2: Table S1. TLR 2/4 expression in wildtype and
Myd88−/− neurons. Un-treated, day 9 in vitro, wildtype and Myd88−/−
primary neuronal cultures were analysed by Q-PCR to determine TLR2 and
TLR4 expression levels. Observed raw GAPDH, TLR2 and TLR4 Ct values are
displayed and no reverse transcriptase (RT) and water controls remained
undetermined (U.D.). Data is expressed as mean ± SEM (n = 4).
Additional file 3: Figure S3. Full Western blot images of Aβ1-42-treated
wildtype and Myd88−/− neuronal cultures. Wildtype and Myd88−/− primary
cultured murine mixed cortical and hippocampal neuronal cultures were
treated with 2.5 μM Aβ1-42 for 24 to 72 h. Western blotting, probing for
p-STAT-3, STAT-3 and β-actin, was performed as described previously
within the Materials and methods section. Bands of interest were
selected from the full-sized Western blot image, as indicated by the red
box, and cropped. This cropped image was then subjected to uniform
image enhancement of contrast and brightness to yield the publication
image seen in Figure 1C. Molecular weights were determined using the
Precision Plus Protein™ WesternC Standard (Bio-Rad, 161-0376) that yields a
colorimetric image only and has been removed from the chemiluminescent
blot image.
Additional file 4: Figure S2. Aβ42-1-treated neurons do not initiate a
type-1 interferon response. Wildtype primary cultured murine mixed cortical
and hippocampal neuronal cultures were treated with 2.5 μM Aβ42-1 (reverse
sequence peptide) for 24 to 72 h. (A) IFNα and (B) IFNβ mRNA levels were
then analysed by Q-PCR (n= 4). (B) Tyrosine 705 phosphorylation of STAT-3
was detected by Western blot in these same cultures. All graphical data is
displayed as mean ± SEM with treatment time on the x axis.
Additional file 5: Figure S4. The type-1 IFN response to Aβ1-42 is
attenuated in an alternate clonal M17 IRF7 shRNA knockdown cell line.
Human BE(2) M17 neuroblastoma cells, transfected with an IRF7 knockdown
(KD) construct or negative control (NC) plasmid, were treated with 7.5 μM
Aβ1-42 for 24 to 96 h. Q-PCR was performed to analyse (A) IFNα and (B) IFNβ
mRNA levels post-treatment (*p < 0.05, **p < 0.01, n = 3 to 4, unmatched
two-way ANOVA, Bonferroni post hoc test). Data shown is from an alternative
clonal cell line to that used in Figures 4 and 5. (C) Levels of IRF7 knockdown
in these cells were also determined by Q-PCR where data is expressed as fold
change normalised to corresponding negative control transfected cells
(nominal value of 1, n= 3). Graphical data is displayed as mean ± SEM.
Additional file 6: Figure S5. Full Western blot images of Aβ1-42-treated
M17 NC and IRF7 KD cell cultures. Human BE(2) M17 neuroblastoma cells,
transfected with an IRF7 knockdown (KD) construct or negative control (NC)
plasmid, were treated with 7.5 μM Aβ1-42 for 24 to 96 h. Western blotting,
probing for p-STAT-3, STAT-3 and β-actin, was performed as described
previously within the Materials and methods section. Bands of interest
were selected from the full-sized western blot image, as indicated by the red
box, and cropped. This cropped image was then subjected to uniform image
enhancement of contrast and brightness to yield the publication image seen
in Figure 4E. Molecular weights were determined using the Precision Plus
Protein™ WesternC Standard (Bio-Rad, 161-0376) that yields a colorimetric
image only and has been removed from the chemiluminescent blot image.
Additional file 7: Figure S6. Full Western blot images of LPS-treated
M17 NC and IRF7 KD cell cultures. Human BE(2) M17 neuroblastoma cells,
transfected with an IRF7 knockdown (KD) construct or negative control
(NC) plasmid, were treated with 100 ng/ml LPS for 0.5 to 24 h. Western
blotting, probing for p-STAT-3, STAT-3 and β-actin, was performed as
described previously within the Materials and methods section. Bands of
interest were selected from the full-sized Western blot image, as
indicated by the red box, and cropped. This cropped image was then
subjected to uniform image enhancement of contrast and brightness to
yield the publication image seen in Figure 4H. Molecular weights were
determined using the Precision Plus Protein™ WesternC Standard (Bio-Rad,
161-0376) that yields a colorimetric image only and has been removed from
the chemiluminescent blot image.Abbreviations
Aβ: amyloid-beta; ACh: acetylcholine; AD: Alzheimer’s disease;
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